Qian Shen1, Xiaoqi Dong1, Xiaoping Tang1, Jianying Zhou1. 1. Department of Respiratory Disease, First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310003, China.
Abstract
BACKGROUND: Venous thromboembolism (VTE) is the well-known complication of cancer, especially among lung cancer patients. The objective of this study is to identify the incidence, risk factors and prognosis of VTE in the patients with non-small cell lung cancer (NSCLC) in an advanced or metastatic stage (stage III or IV). We hypothesized that NSCLC patients associated with VTE may lead to poor prognosis. METHODS: From 2012 to 2015, we retrospectively investigated 1,560 patients diagnosed with lung cancer in stage III or IV. Each VTE patient was matched with three control patients according to gender, age, pathology, clinical stage and the diagnosed time. Univariate and multivariate analyses were used in the study. RESULTS: Among the 1,560 patients in our study, 32 (2.0%) developed VTE in locally advanced or metastatic stage lung cancer. Weight loss, serous effusion, the absence of the EGFR mutation, poor performance status (PS), hypoalbuminemia, hyponatremia, long prothrombin time (PT), and elevated levels of C-reaction-protein (CRP) and D-dimer were found to be associated with an increased risk of VTE by univariate analyses. The multivariate analyses revealed that weight loss, poor PS, increased CRP and long PT were significantly related to VTE. Overall survival (OS) from diagnosis was significantly shorter in patients with VTE (medians 14.2 vs. 24.4 months; P<0.001). CONCLUSIONS: The incidence of VTE was high among advanced NSCLC patients, particularly for those with weight loss, poor PS, increased CRP and long PT. Moreover, the patients with VTE complications may have a poorer prognosis.
BACKGROUND: Venous thromboembolism (VTE) is the well-known complication of cancer, especially among lung cancer patients. The objective of this study is to identify the incidence, risk factors and prognosis of VTE in the patients with non-small cell lung cancer (NSCLC) in an advanced or metastatic stage (stage III or IV). We hypothesized that NSCLC patients associated with VTE may lead to poor prognosis. METHODS: From 2012 to 2015, we retrospectively investigated 1,560 patients diagnosed with lung cancer in stage III or IV. Each VTE patient was matched with three control patients according to gender, age, pathology, clinical stage and the diagnosed time. Univariate and multivariate analyses were used in the study. RESULTS: Among the 1,560 patients in our study, 32 (2.0%) developed VTE in locally advanced or metastatic stage lung cancer. Weight loss, serous effusion, the absence of the EGFR mutation, poor performance status (PS), hypoalbuminemia, hyponatremia, long prothrombin time (PT), and elevated levels of C-reaction-protein (CRP) and D-dimer were found to be associated with an increased risk of VTE by univariate analyses. The multivariate analyses revealed that weight loss, poor PS, increased CRP and long PT were significantly related to VTE. Overall survival (OS) from diagnosis was significantly shorter in patients with VTE (medians 14.2 vs. 24.4 months; P<0.001). CONCLUSIONS: The incidence of VTE was high among advanced NSCLC patients, particularly for those with weight loss, poor PS, increased CRP and long PT. Moreover, the patients with VTE complications may have a poorer prognosis.
Authors: Joanne L Yu; Linda May; Vladimir Lhotak; Siranoush Shahrzad; Senji Shirasawa; Jeffrey I Weitz; Brenda L Coomber; Nigel Mackman; Janusz W Rak Journal: Blood Date: 2004-10-19 Impact factor: 22.113
Authors: Richard Li; Gretchen Hermann; Elizabeth Baldini; Aileen Chen; David Jackman; David Kozono; Paul Nguyen; Anju Nohria; Graham Powell; Raymond Mak Journal: Lung Cancer Date: 2016-03-16 Impact factor: 5.705
Authors: Alex J Walker; David R Baldwin; Tim R Card; Helen A Powell; Richard B Hubbard; Matthew J Grainge Journal: Br J Cancer Date: 2016-11-01 Impact factor: 7.640
Authors: Francisco Galeano-Valle; Lucía Ordieres-Ortega; Crhistian Mario Oblitas; Jorge Del-Toro-Cervera; Luis Alvarez-Sala-Walther; Pablo Demelo-Rodríguez Journal: Int J Mol Sci Date: 2021-03-05 Impact factor: 5.923
Authors: Joanna Rupa-Matysek; Marta Lembicz; Eliza Katarzyna Rogowska; Lidia Gil; Mieczysław Komarnicki; Halina Batura-Gabryel Journal: Med Oncol Date: 2018-04-03 Impact factor: 3.064